Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects

NCT06506175 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight or Obese, Type 2 Diabetes

Interventions

DRUG: HRS9531 tablets

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.